• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

FDA Approval of Remdesivir - A Step in the Right Direction.

作者信息

Rubin Daniel, Chan-Tack Kirk, Farley John, Sherwat Adam

机构信息

From the Division of Biometrics IV, Office of Biostatistics (D.R.), the Division of Antivirals, Office of Infectious Diseases (K.C.-T.), and the Office of Infectious Diseases (J.F., A.S.), Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD.

出版信息

N Engl J Med. 2020 Dec 31;383(27):2598-2600. doi: 10.1056/NEJMp2032369. Epub 2020 Dec 2.

DOI:10.1056/NEJMp2032369
PMID:33264539
Abstract
摘要

相似文献

1
FDA Approval of Remdesivir - A Step in the Right Direction.美国食品药品监督管理局对瑞德西韦的批准——朝着正确方向迈出的一步。
N Engl J Med. 2020 Dec 31;383(27):2598-2600. doi: 10.1056/NEJMp2032369. Epub 2020 Dec 2.
2
'A very, very bad look' for remdesivir.瑞德西韦的情况“非常、非常不妙”。
Science. 2020 Nov 6;370(6517):642-643. doi: 10.1126/science.370.6517.642.
3
Remdesivir Approved to Treat COVID-19 Amid Controversy.瑞德西韦在争议声中获批用于治疗新冠肺炎。
Am J Nurs. 2021 Jan 1;121(1):22-24. doi: 10.1097/01.NAJ.0000731640.35662.2c.
4
Commentary: "Emergency Use Authorization for Remdesivir: A Pediatric Perspective".评论：“瑞德西韦的紧急使用授权：儿科视角”
Pediatr Infect Dis J. 2020 Sep;39(9):e234. doi: 10.1097/INF.0000000000002799.
5
An EUA for baricitinib (Olumiant) for COVID-19.巴瑞替尼（Olumiant）用于治疗新冠肺炎的紧急使用授权。
Med Lett Drugs Ther. 2020 Dec 28;62(1614):202-203.
6
Remdesivir: Critical Clinical Appraisal for COVID 19 Treatment.瑞德西韦：COVID-19 治疗的关键临床评价。
Drug Res (Stuttg). 2021 Mar;71(3):138-148. doi: 10.1055/a-1288-4078. Epub 2020 Oct 29.
7
A Potential Antiviral Treatment for COVID-19: Remdesivir.一种针对新冠病毒病的潜在抗病毒疗法：瑞德西韦。
Clin Nurse Spec. 2020 Nov/Dec;34(6):257-260. doi: 10.1097/NUR.0000000000000549.
8
Missed Opportunities on Emergency Remdesivir Use.瑞德西韦紧急使用中的错失机会
JAMA. 2020 Jul 28;324(4):331-332. doi: 10.1001/jama.2020.11932.
9
Remdesivir: a pendulum in a pandemic.瑞德西韦：大流行中的钟摆。
BMJ. 2020 Nov 24;371:m4560. doi: 10.1136/bmj.m4560.
10
Assessing the evidence on remdesivir.评估关于瑞德西韦的证据。
Lancet Infect Dis. 2021 Dec;21(12):1630-1631. doi: 10.1016/S1473-3099(21)00695-2.

引用本文的文献

1
Cardiovascular Safety of COVID-19 Treatments: A Disproportionality Analysis of Adverse Event Reports from the WHO VigiBase.新型冠状病毒肺炎治疗的心血管安全性：来自世界卫生组织药物不良反应数据库不良事件报告的不成比例性分析
Infect Dis Ther. 2025 Sep 11. doi: 10.1007/s40121-025-01225-z.
2
Cardiac adverse events associated with remdesivir in COVID-19 patients: a systematic review and meta-analysis of randomised controlled trials.新冠患者中与瑞德西韦相关的心脏不良事件：随机对照试验的系统评价和荟萃分析
BMJ Open. 2025 Jul 18;15(7):e089977. doi: 10.1136/bmjopen-2024-089977.
3
Impact of the COVID-19 pandemic on the consumption of antibiotics and the emergence of AMR: case study in a general hospital.
新冠疫情对抗生素使用及抗菌药物耐药性产生的影响：一家综合医院的案例研究
Front Public Health. 2025 Jun 23;13:1584574. doi: 10.3389/fpubh.2025.1584574. eCollection 2025.
4
Remdesivir associated with reduced mortality in hospitalized COVID-19 patients: treatment effectiveness using real-world data and natural language processing.瑞德西韦与住院COVID-19患者死亡率降低相关：利用真实世界数据和自然语言处理的治疗效果
BMC Infect Dis. 2025 Apr 12;25(1):513. doi: 10.1186/s12879-025-10817-6.
5
Comparative Analysis of Neuropsychiatric Adverse Reactions Associated with Remdesivir and Nirmatrelvir/Ritonavir in COVID-19 Treatment: Insights from EudraVigilance Data.瑞德西韦与奈玛特韦/利托那韦在新冠治疗中相关神经精神不良反应的对比分析：来自欧洲药品管理局药物警戒数据的见解
J Clin Med. 2025 Mar 11;14(6):1886. doi: 10.3390/jcm14061886.
6
The impact of remdesivir on SARS-CoV-2 evolution in vivo.瑞德西韦对体内严重急性呼吸综合征冠状病毒2（SARS-CoV-2）进化的影响。
JCI Insight. 2025 Jan 21;10(4):e182376. doi: 10.1172/jci.insight.182376.
7
In Vitro Screening of an In-House Library of Structurally Distinct Chemotypes Towards the Identification of Novel SARS-CoV-2 Inhibitors.对一组结构各异化学型的内部文库进行体外筛选以鉴定新型严重急性呼吸综合征冠状病毒2（SARS-CoV-2）抑制剂
Pharmaceuticals (Basel). 2024 Dec 11;17(12):1668. doi: 10.3390/ph17121668.
8
Remdesivir Effectiveness in Reducing the Risk of 30-Day Readmission in Vulnerable Patients Hospitalized for COVID-19: A Retrospective US Cohort Study Using Propensity Scores.瑞德西韦对降低COVID-19住院脆弱患者30天再入院风险的有效性：一项使用倾向评分的美国回顾性队列研究。
Clin Infect Dis. 2024 Dec 13;79(Suppl 4):S167-S177. doi: 10.1093/cid/ciae511.
9
Repurposed Drugs during the Outbreak of Pandemic COVID-19: A Mini-Review on Their Molecular Structures and Hit-and-Trial Results.新冠大流行期间的药物再利用：关于其分子结构和试错结果的综述
ACS Omega. 2024 Aug 20;9(35):36858-36864. doi: 10.1021/acsomega.4c05357. eCollection 2024 Sep 3.
10
Safety and effectiveness of remdesivir in hospitalized patients with COVID-19 and severe renal impairment: experience at a large medical center.瑞德西韦在 COVID-19 住院患者和严重肾功能损害患者中的安全性和有效性：一家大型医疗中心的经验。
Ann Med. 2024 Dec;56(1):2361843. doi: 10.1080/07853890.2024.2361843. Epub 2024 Jun 3.